Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 632 articles

Articles by Daniel Marsh

Palantir Stock Rises Ahead of Key U.S. Economic Data Releases
Markets

Palantir Stock Rises Ahead of Key U.S. Economic Data Releases

Palantir shares gained 4.5% on Friday as software stocks rebounded, with investors shifting focus to upcoming inflation and employment reports.

PLTR XLK
AI Spending Ignites Chip Stock Rally, Eyes on Economic Data
Markets

AI Spending Ignites Chip Stock Rally, Eyes on Economic Data

Semiconductor stocks surged Friday, led by Nvidia and AMD, as major tech capex forecasts and a bullish industry outlook fueled optimism. The rally's sustainability hinges on upcoming inflation and jobs data.

NVDA AMD AVGO INTC MU SMH AMAT AAPL AMZN XLK
AI Chip Stocks Surge on Tech Spending Plans; CPI and Nvidia Earnings Loom
Markets

AI Chip Stocks Surge on Tech Spending Plans; CPI and Nvidia Earnings Loom

Nvidia and AMD rallied sharply Friday as the Dow closed above 50,000, fueled by Big Tech's massive AI capital expenditure plans. The focus now shifts to inflation data and Nvidia's upcoming earnings.

NVDA AMD AMZN AVGO MSFT GOOGL XLK
Dow Jones Tops 50,000 Milestone as AI Rally Fuels Record Close
Markets

Dow Jones Tops 50,000 Milestone as AI Rally Fuels Record Close

The Dow Jones Industrial Average closed above 50,000 for the first time on Friday, driven by a rebound in chip stocks. Key inflation and jobs data releases have been postponed to next week.

CAT NVDA AMZN KO CSCO XLK
GE Aerospace Surges on Dividend Boost Amid Supply Chain and Engine Scrutiny
Markets

GE Aerospace Surges on Dividend Boost Amid Supply Chain and Engine Scrutiny

GE Aerospace shares climbed nearly 5% to $321 after announcing a 31% dividend increase to $0.47 per share, while facing supply chain pressures and a potential engine durability review.

GE HON RTX BA DOW
AMD Surges 8% as Cloud Giants Boost AI Spending, Eyes on Inflation Data
Markets

AMD Surges 8% as Cloud Giants Boost AI Spending, Eyes on Inflation Data

AMD shares rallied 8.2% to $208.44 Friday, lifted by Amazon and Alphabet's plans to increase data-center investments. The Philadelphia Semiconductor Index jumped nearly 6%.

AMD NVDA AMZN GOOG GOOGL XLK
Caterpillar Powers Dow Past 50,000 as Investors Shift to Industrials
Markets

Caterpillar Powers Dow Past 50,000 as Investors Shift to Industrials

Caterpillar surged 7% to $726.20, driving the Dow Jones Industrial Average above the 50,000 milestone. Investors rotated capital from technology into industrial stocks ahead of key U.S. economic data releases next week.

CAT DE CNH
P&G Shares Gain as Investors Eye Defensive Rotation, Upcoming Economic Data
Markets

P&G Shares Gain as Investors Eye Defensive Rotation, Upcoming Economic Data

Procter & Gamble stock rose 0.37% to $159.17 amid a shift toward defensive, dividend-paying equities. Key U.S. jobs and inflation reports are due next week, alongside P&G's dividend payment.

PG CLX CL KMB UL KO MCD CSCO DIA SPY
AbbVie Gains on Moody's Credit Upgrade, Focus Shifts to Immunology Portfolio
Markets

AbbVie Gains on Moody's Credit Upgrade, Focus Shifts to Immunology Portfolio

AbbVie shares rose 2% to $223.43 after Moody's upgraded its credit rating to A2 with a stable outlook. Investors now watch demand and pricing for Skyrizi and Rinvoq amid Humira competition.

ABBV
SK hynix Shares Dip Amid Tech Sell-Off, Dividend Dates Set
Markets

SK hynix Shares Dip Amid Tech Sell-Off, Dividend Dates Set

SK hynix closed at 839,000 won, down 0.36%, as the KOSPI fell 1.4% to end a six-week rally. The company announced a 1,875 won per share dividend with key dates in late February.

SSNLF AAPL XLK
Roche's MS Drug Trial Results Spark Investor Scrutiny Ahead of Key Presentation
Markets

Roche's MS Drug Trial Results Spark Investor Scrutiny Ahead of Key Presentation

Roche's experimental multiple sclerosis drug fenebrutinib met its primary endpoint in a late-stage study but showed higher liver enzyme elevations and fatalities versus Ocrevus. Investors await Monday's detailed data webcast.

RHHBY XLV
Roche's MS Drug Trial Results Set Stage for Monday Investor Scrutiny
Markets

Roche's MS Drug Trial Results Set Stage for Monday Investor Scrutiny

Roche's fenebrutinib met its primary endpoint in a late-stage PPMS trial, showing non-inferiority to Ocrevus but with higher liver enzyme elevations and fatal cases. Shares closed at 356.40 Swiss francs, down 0.6%.

RHHBY